NBIX logo

NBIX Neurocrine Biosciences, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$150.57
-6.02 (-3.84%)

Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental com…

Market Cap: $15.24Bwww.neurocrine.com

Price

No data yet.

Social Signal Score

59
5d
60
2 mentions
—
30d
59
21 mentions
—
60d
59
30 mentions
—
90d
59
37 mentions
—
news: 30 · rss: 6 · marketaux: 1

Analyst Ratings

37 analysts
Buyconsensus
Strong Buy 0Buy 32Hold 5Sell 0Strong Sell 0
Avg price target$203.41+35.1%
Low $165Median $210High $225
Current Consensus

Revenue

$1.12B
$0.00$374.23M$748.47M$1.12B
Dec 2016Sep 2026

Analyst Estimates

FY2025
$5.04
$4.90–$5.41
12 analysts
FY2026
$7.33+46% YoY
$6.68–$7.94
14 analysts
FY2027
$9.70+32% YoY
$6.64–$12.86
15 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Kyle W. Gano
Sector
Healthcare
Industry
Biotechnology
Employees
2,500
Beta
0.33
Country
US
Piotroski score
5 / 9 (Middling)
Altman Z-score
6.82
www.neurocrine.com